SCHEMBL502019

SCHEMBL502019

C[Si](C)(C)c1cc(C(N)=O)cc([Si](C)(C)C)c1-c1ccccc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.51
ALDH1A1 P00352 4/20 0.44
TSHR P16473 2/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
BCAT2 O15382 1/20 0.40
SOS1 Q07889 1/20 0.40
DHODH Q02127 2/20 0.40
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
PARP1 P09874 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8554492 0.77 MYC (0.51) MYCALDH1A1TSHRKDM4EUSP2
SCHEMBL11217790 0.71 MYC (0.69) MYCALDH1A1KDM4ESOS1MAPT
SCHEMBL7822299 0.69 BCAT2 (0.69) MYCALDH1A1TSHRKDM4ENPC1
SCHEMBL106081 0.69 ALDH1A1 (0.56) MYCALDH1A1TSHRKDM4EUSP2
SCHEMBL27659760 0.69 BCAT2 (0.69) MYCALDH1A1TSHRKDM4ENPC1
SCHEMBL6980584 0.69 BCAT2 (0.63) MYCALDH1A1TSHRKDM4ENPC1
SCHEMBL27361722 0.69 BCAT2 (0.58) MYCTSHRNPC1RAB9ABCAT2
SCHEMBL9512847 0.69 MYC (1.00) MYCALDH1A1TSHRKDM4EUSP2
Hydrochloric Acid SCHEMBL9411948 0.68 ALDH1A1 (0.54) MYCALDH1A1TSHRKDM4EUSP2
SCHEMBL7738392 0.68 ALDH1A1 (0.50) ALDH1A1TSHRKDM4EUSP2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030360-B2 Applying 4-(2,4-bistrimethylsilyphenylcarboxamide) benzoic acid; warts, eczema, dandruff KEMPHYS LTD. (JP) 2011-10-04 US claimed
EP-0768084-B1 CANCEROUS METASTASIS INHIBITOR TAIHO PHARMACEUTICAL CO LTD (JP) 2002-09-11 EP claimed
EP-0768084-A1 CANCEROUS METASTASIS INHIBITOR TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-04-16 EP claimed
JP-2247185-A None JP disclosed
US-8105833-B2 Method for forming organ RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-01-31 US disclosed
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS INC. (US) 2011-12-29 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-8030360-B2 Applying 4-(2,4-bistrimethylsilyphenylcarboxamide) benzoic acid; warts, eczema, dandruff KEMPHYS LTD. (JP) 2011-10-04 US disclosed
US-8030360-B2 Applying 4-(2,4-bistrimethylsilyphenylcarboxamide) benzoic acid; warts, eczema, dandruff KEMPHYS LTD. (JP) 2011-10-04 US disclosed
US-7998971-B2 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection BRAINCELLS INC. (US) 2011-08-16 US disclosed
US-20110092464-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-04-21 US disclosed
US-20070270449-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2007-11-22 US disclosed
US-20070244143-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS BRAINCELLS, INC (US) 2007-10-18 US disclosed
CN-1964709-A Memory fixation promoter RES FOUND ITSUU LAB (JP) 2007-05-16 CN disclosed
US-20070078083-A1 MODULATION OF NEUORGENESIS BY HDac INHIBITION BRAINCELLS, INC. (US) 2007-04-05 US disclosed
US-20070049576-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2007-03-01 US disclosed
WO-2005087219-A1 MEMORY FIXATION ACCELERATOR RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2005-09-22 WO disclosed
EP-0768084-B1 CANCEROUS METASTASIS INHIBITOR TAIHO PHARMACEUTICAL CO LTD (JP) 2002-09-11 EP disclosed
EP-0768084-A1 CANCEROUS METASTASIS INHIBITOR TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-04-16 EP disclosed
JP-H02247185-A NOVEL BENZOIC ACID DERIVATIVE AND PRODUCTION THEREOF SHUDO KOICHI 1990-10-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 MYC 723/4885ALDH1A1 2164/4885TSHR 302/4885
US-20070270449-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR5A, HTR6, GAP43 MYC 435/4885ALDH1A1 2530/4885TSHR 292/4885
US-20070078083-A1 MODULATION OF NEUORGENESIS BY HDac INHIBITION DCX, BDNF, NTRK2 MYC 559/4885ALDH1A1 1837/4885TSHR 1561/4885
US-20110092464-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN DCX, NGF, BDNF MYC 791/4885ALDH1A1 1591/4885TSHR 1891/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF MYC 1566/4885ALDH1A1 1565/4885TSHR 1873/4885
US-20070244143-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS GAP43, BDNF, DCX MYC 734/4885ALDH1A1 3011/4885TSHR 856/4885
US-20070049576-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 MYC 723/4885ALDH1A1 2164/4885TSHR 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.